Carrier Status for the Common R501X and 2282del4 Filaggrin Mutations Is Not Associated with Hearing Phenotypes in 5377 Children from the ALSPAC Cohort

Santiago Rodriguez1,2*, Amanda J. Hall3, Raquel Granell4, W. H. Irwin McLean5, Alan D. Irvine6, Colin N. A. Palmer7, George Davey Smith2, John Henderson8, Ian N. M. Day1,2

1 Bristol Genetic Epidemiology Laboratories (BGEL), Department of Social Medicine, University of Bristol, Bristol, United Kingdom, 2 MRC Centre for Causal Analyses in Translational Epidemiology (CAiTE), Department of Social Medicine, University of Bristol, Bristol, United Kingdom, 3 Centre for Hearing and Balance Studies, University of Bristol, Bristol, United Kingdom, 4 Department of Social Medicine, University of Bristol, Bristol, United Kingdom, 5 Epithelial Genetics Group, Human Genetics Unit, Division of Pathology and Neuroscience, University of Dundee, Ninewells Hospital and Medical School, Dundee, United Kingdom, 6 Department of Paediatric Dermatology, Our Lady’s Hospital for Sick Children, Dublin, Ireland, 7 Population Pharmacogenetics Group, Biomedical Research Centre, University of Dundee, Ninewells Hospital and Medical School, Dundee, United Kingdom, 8 Department of Community Based Medicine, University of Bristol, Bristol, United Kingdom

Abstract

Background: Filaggrin is a major protein in the epidermis. Several mutations in the filaggrin gene (FLG) have been associated with a number of conditions. Filaggrin is expressed in the tympanic membrane and could alter its mechanical properties, but the relationship between genetic variation in FLG and hearing has not yet been tested.

Methodology/Principal Findings: We examined whether loss-of-function mutations R501X and 2282del4 in the FLG gene affected hearing in children. Twenty eight hearing variables representing five different aspects of hearing at age nine years in 5,377 children from the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort were tested for association with these mutations. No evidence of association was found between R501X or 2282del4 (or overall FLG mutation carrier status) and any of the hearing phenotypes analysed.

Conclusions/Significance: In conclusion, carrier status for common filaggrin mutations does not affect hearing in children.

References:

1. Rodriguez S, Hall AJ, Granell R, McLean WH, Irvine AD, et al. (2009) Carrier Status for the Common R501X and 2282del4 Filaggrin Mutations Is Not Associated with Hearing Phenotypes in 5377 Children from the ALSPAC Cohort. PLoS ONE 4(6): e5784. doi:10.1371/journal.pone.0005784

Editor: Iris Schrijver, Stanford University, United States of America

Published: June 3, 2009

Copyright: © 2009 Rodriguez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The Wellcome Trust, the University of Bristol and the University of Dundee provide core support for ALSPAC. Measurements of hearing ability were supported by the core support for ALSPAC. The genotyping was supported by grants from British Skin Foundation/National Eczema Association, The Pachyonychia Congenita Project and The Dystrophic Epidermolysis Bullosa Research Association. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: WHIM has patents related to potential therapeutic manipulation of filaggrin and to diagnostic applications of filaggrin screening. ADI has acted as a consultant to Novartis Pharmaceuticals. The remaining authors stipulate no conflicts of interests.

* E-mail: santi.rodriguez@bristol.ac.uk
Table 1. Effect of FLG R501X on 30 hearing variables as tested by one-way ANOVA tests.

| Variable                        | FLG  | N  | Mean | SD  | F   | P    |
|--------------------------------|------|----|------|-----|-----|------|
| **Right ear**                  |      |    |      |     |     |      |
| Air conduction hearing threshold (dB HL) |      |    |      |     |     |      |
| 0.5 kHz AA                     | 4952 | 6.20 | 7.24 | 0.12 | 0.7328 |
| 0.5 kHz Aa                     | 219  | 6.37 | 6.75 |     |      |
| 1 kHz AA                       | 5026 | 4.38 | 7.66 | 0.23 | 0.6291 |
| 1 kHz Aa                       | 223  | 4.13 | 6.61 |     |      |
| 2 kHz AA                       | 5025 | 4.04 | 7.33 | 0.47 | 0.4914 |
| 2 kHz Aa                       | 223  | 3.70 | 5.80 |     |      |
| 4 kHz AA                       | 5024 | 3.85 | 8.34 | 1.12 | 0.2908 |
| 4 kHz Aa                       | 223  | 3.25 | 7.90 |     |      |
| 8 kHz AA                       | 4932 | 6.42 | 7.30 | 0.02 | 0.8952 |
| 8 kHz Aa                       | 219  | 6.42 | 6.57 |     |      |
| Average 0.5, 1, 2, 4, 8 kHz AA | 4926 | 5.47 | 6.83 | 0.33 | 0.5665 |
| Average 0.5, 1, 2, 4, 8 kHz Aa | 217  | 5.22 | 5.63 |     |      |
| Bone conduction hearing threshold (dB HL) |      |    |      |     |     |      |
| 0.5 kHz AA                     | 4859 | –1.24 | 6.53 | 0.06 | 0.8069 |
| 0.5 kHz Aa                     | 215  | –1.35 | 6.02 |     |      |
| 1 kHz AA                       | 5000 | –2.30 | 6.52 | 0.07 | 0.7956 |
| 1 kHz Aa                       | 222  | –2.18 | 5.81 |     |      |
| 2 kHz AA                       | 4868 | 0.95  | 7.26 | 0.20 | 0.6557 |
| 2 kHz Aa                       | 215  | 0.72  | 6.84 |     |      |
| Average 0.5, 1, 2 kHz AA       | 4854 | –0.89 | 5.38 | 0.01 | 0.9085 |
| Average 0.5, 1, 2 kHz Aa       | 215  | –0.93 | 5.01 |     |      |
| **Left ear**                   |      |    |      |     |     |      |
| TEOAE amplitude (dB SPL)       |      |    |      |     |     |      |
| 1 kHz AA                       | 3865 | –8.75 | 6.96 | 0.03 | 0.8677 |
| 1 kHz Aa                       | 164  | –8.66 | 7.56 |     |      |
| 2 kHz AA                       | 3899 | –10.16 | 6.74 | 0.06 | 0.8092 |
| 2 kHz Aa                       | 165  | –10.29 | 6.55 |     |      |
| 3 kHz AA                       | 3893 | –12.12 | 7.14 | 1.24 | 0.2661 |
| 3 kHz Aa                       | 166  | –12.75 | 7.05 |     |      |
| 4 kHz AA                       | 3906 | –13.81 | 7.57 | 0.53 | 0.4680 |
| 4 kHz Aa                       | 166  | –14.24 | 6.86 |     |      |
| Total response                 | 3917 | 9.62  | 5.69 | 0.05 | 0.8229 |
| Total response                 | 166  | 9.52  | 5.36 |     |      |
| **Right ear**                  |      |    |      |     |     |      |
| TEOAE amplitude (dB SPL)       |      |    |      |     |     |      |
| 1 kHz AA                       | 3704 | –7.66 | 6.91 | 2.63 | 0.1048 |
| 1 kHz Aa                       | 154  | –6.73 | 7.20 |     |      |
| 2 kHz AA                       | 3765 | –9.04 | 6.52 | 3.50 | 0.0615 |
| 2 kHz Aa                       | 154  | –8.04 | 6.11 |     |      |
Therefore, FLG mutations could affect hearing. In addition, filaggrin has been localised immunohistochemically in middle ear cholesteatoma in humans [11], this condition leading to an alteration of epidermal differentiation in middle ear [12]. Expression of FLG in these locations affecting the cornified envelope of the tympanic epidermis has the potential to influence hearing. The high prevalence of FLG mutations could reflect chance, but selective advantage through a trait such as hearing is another possibility. We hypothesized that such changes would affect air but not bone conduction as they affect tympanic membrane and not neural mechanisms.

Clinical evidence available relates impaired keratinization to the filaggrin mutations R501X and 2282del4. To date, there has been no consideration of the possible effects with respect to filaggrin expression in the tympanic membrane. Based on this evidence we tested whether carrier status for a single copy of these mutations is a risk or protective factor for hearing loss/enhanced hearing in an epidemiological survey of 5,377 UK children with detailed phenotypic information for a range of hearing phenotypes.

Materials and Methods

Participants

ALSPAC is a longitudinal, population-based birth cohort study that recruited 14,541 pregnant women residing in Avon, United Kingdom, with expected dates of delivery between April 1, 1991, and December 31, 1992. There were 14,062 liveborn children. The study protocol has been described previously [13,14] and further details are available on the ALSPAC Web site (http://www.bris.ac.uk/alspac). Ethical approval for all aspects of data collection was obtained from the ALSPAC Law and Ethics Committee (institutional review board 00003312). Written informed consent for the study was obtained.

Genotyping

Genotyping was done as previously described [4]. In brief, R501X and 2282del4 were genotyped with the TaqMan allelic discrimination assays (Applied Biosystems, Foster City, California) in 384-well plates. Double-checking with other technical approaches was performed in a substantial fraction of the samples, including all the identified homozygotes of both variants and all 2282del4 carriers.

Hearing variables

All study participants were invited to a research clinic at 9 years of age where five different hearing phenotypes were measured: hearing thresholds, transient evoked (TE) otoacoustic emission (OAE) amplitude, middle ear compliance and pressure.

For these phenotypes, a total of 28 variables were analysed: hearing thresholds at five frequencies (0.5, 1, 2, 4 and 8 kHz) for air conduction and three frequencies (0.5, 1, 2 kHz) for bone conduction were measured. Tympanometry was used to measure middle ear compliance and middle ear pressure. TEOAE were evoked using a click stimulus of approximately 70 dB SPL (linear mode), and the response amplitude obtained for the total response and at frequency bands 1–4 kHz. All measures (except bone conduction thresholds) were obtained for both left and right ears.

Since both mutations are inactivating mutations likely to have similar or identical effects and homozygotes and compound heterozygotes are rare, we also undertook a combined analysis (one degree of freedom) for each variable for FLG mutation carrier vs FLG mutation non-carrier.

In addition to the analysis of each variable in all individuals, we tested whether each of the two mutations was associated with better versus worse hearing, using a cut off of $<0$ dB, both for hearing thresholds (right and left), and for bone conduction acute hearing thresholds. The effect of both mutations was also analysed by testing the association between each of the mutations and better versus worse cochlear function/middle ear transmission (worse cochlear function defined as the bottom quartile of the TEOAE amplitude distribution).

We tested whether R501X or 2282del4 associated with bilateral middle ear effusion. Finally, we tested whether the filaggrin

| Variable                      | N  | Mean | SD  | F   | P   |
|-------------------------------|----|------|-----|-----|-----|
| **3 kHz**                     |    |      |     |     |     |
| AA                            | 3761 | -11.44 | 7.18 | 0.08 | 0.7736 |
| Aa                            | 154  | -11.27 | 6.76 |     |     |
| **4 kHz**                     |    |      |     |     |     |
| AA                            | 3757 | -13.54 | 7.42 | 0.60 | 0.4401 |
| Aa                            | 152  | -14.01 | 7.07 |     |     |
| **Total response**            |    |      |     |     |     |
| AA                            | 3776 | 10.46  | 5.65 | 2.89 | 0.0894 |
| Aa                            | 154  | 11.25  | 5.46 |     |     |

Table 1. cont.

doi:10.1371/journal.pone.0005784.t001
Table 2. Effect of FLG 2282del4 on 30 hearing variables as tested by one-way ANOVA tests.

|                | 2282del4 | N | Mean  | SD   | F    | P    |
|----------------|----------|---|-------|------|------|------|
| **Right ear**  |          |   |       |      |      |      |
| Air conduction hearing threshold (dB HL) | 0.5 kHz  | AA | 4932  | 6.19 | 7.19 | 0.32 | 0.7243 |
|                |          | Aa | 238   | 6.55 | 7.83 |      |      |
|                |          | aa | 2     | 7.50 | 3.54 |      |      |
|                |          |    | 1 kHz |      |      |      |      |
|                |          | AA | 5010  | 4.32 | 7.53 | 2.29 | 0.1018 |
|                |          | Aa | 238   | 5.36 | 9.15 |      |      |
|                |          | aa | 2     | 7.50 | 3.54 |      |      |
|                |          |    | 2 kHz |      |      |      |      |
|                |          | AA | 5009  | 4.00 | 7.20 | 5.16 | 0.0057 |
|                |          | Aa | 238   | 4.39 | 8.43 |      |      |
|                |          | aa | 2     | 20.00| 21.21|      |      |
|                |          |    | 4 kHz |      |      |      |      |
|                |          | AA | 5008  | 3.80 | 8.30 | 0.51 | 0.5999 |
|                |          | Aa | 238   | 4.35 | 8.71 |      |      |
|                |          | aa | 2     | 2.50 | 3.54 |      |      |
|                |          |    | 8 kHz |      |      |      |      |
|                |          | AA | 4915  | 9.01 | 10.05| 0.32 | 0.7282 |
|                |          | Aa | 234   | 9.53 | 10.09|      |      |
|                |          | aa | 2     | 7.50 | 3.54 |      |      |
|                |          |    | Average 0.5, 1, 2, 4, 8 kHz |      |      |      |      |
|                |          | AA | 4908  | 5.43 | 6.26 | 1.40 | 0.2456 |
|                |          | Aa | 234   | 6.06 | 7.29 |      |      |
|                |          | aa | 2     | 9.00 | 4.24 |      |      |
| **Left ear**   |          |   |       |      |      |      |
| Air conduction hearing threshold (dB HL) | 0.5 kHz  | AA | 4934  | 6.48 | 7.27 | 0.05 | 0.9520 |
|                |          | Aa | 238   | 6.37 | 7.20 |      |      |
|                |          | aa | 2     | 7.50 | 3.54 |      |      |
|                |          |    | 1 kHz |      |      |      |      |
|                |          | AA | 5009  | 4.48 | 7.59 | 0.03 | 0.9664 |
|                |          | Aa | 238   | 4.60 | 8.01 |      |      |
|                |          | aa | 2     | 5.00 | 7.07 |      |      |
|                |          |    | 2 kHz |      |      |      |      |
|                |          | AA | 5007  | 4.20 | 7.44 | 0.38 | 0.6855 |
|                |          | Aa | 238   | 4.62 | 8.19 |      |      |
|                |          | aa | 2     | 5.00 | 0.00 |      |      |
|                |          |    | 4 kHz |      |      |      |      |
|                |          | AA | 5005  | 4.67 | 8.54 | 0.34 | 0.7106 |
|                |          | Aa | 238   | 4.50 | 8.59 |      |      |
|                |          | aa | 2     | 0.00 | 7.07 |      |      |
|                |          |    | 8 kHz |      |      |      |      |
|                |          | AA | 4913  | 9.15 | 10.32| 0.10 | 0.9009 |
|                |          | Aa | 234   | 8.85 | 10.60|      |      |
|                |          | aa | 2     | 10.00| 0.00 |      |      |
|                |          |    | Average 0.5, 1, 2, 4, 8 kHz |      |      |      |      |
|                |          | AA | 4910  | 5.75 | 6.23 | 0.01 | 0.9889 |
|                |          | Aa | 234   | 5.81 | 6.99 |      |      |
|                |          | aa | 2     | 5.50 | 3.54 |      |      |
| Bone conduction hearing threshold (dB HL) | 0.5 kHz  | AA | 4840  | −1.25| 6.45 | 0.44 | 0.6461 |
|                |          | Aa | 233   | −1.05| 7.72 |      |      |
|                |          | aa | 2     | 2.50 | 10.61|      |      |
|                |          |    | 1 kHz |      |      |      |      |
|                |          | AA | 4984  | −2.30| 6.39 | 0.58 | 0.5610 |
|                |          | Aa | 237   | −2.19| 8.27 |      |      |
|                |          | aa | 2     | 2.50 | 3.54 |      |      |
|                |          |    | 2 kHz |      |      |      |      |
|                |          | AA | 4849  | 0.93 | 7.17 | 0.34 | 0.7145 |
|                |          | Aa | 233   | 1.03 | 8.62 |      |      |
|                |          | aa | 2     | 5.00 | 7.07 |      |      |
|                |          |    | Average 0.5, 1, 2 kHz |      |      |      |      |
|                |          | AA | 4835  | −0.90| 5.27 | 0.72 | 0.4870 |
|                |          | Aa | 233   | −0.74| 7.19 |      |      |
|                |          | aa | 2     | 3.33 | 2.36 |      |      |
|                | 2282del4 | N  | Mean | SD  | F    | P     |
|----------------|----------|----|------|-----|------|-------|
| Left ear       |          |    |      |     |      |       |
| TEOAE amplitude (dB SPL) |          |    |      |     |      |       |
| 1 kHz          |          |    |      |     |      |       |
| AA             | 3838     | 191| –8.68| 6.62| 0.04 | 0.9621|
| Aa             | 1        | 1  | –7.10| 0   | 0.04 | 0.9621|
| aa             | 1        | 1  | –7.10| 0   | 0.04 | 0.9621|
| 2 kHz          |          |    |      |     |      |       |
| AA             | 3871     | 193| –10.60| 6.80| 0.17 | 0.8443|
| Aa             | 1        | 1  | –10.60| 0   | 0.17 | 0.8443|
| aa             | 1        | 1  | –10.60| 0   | 0.17 | 0.8443|
| 3 kHz          |          |    |      |     |      |       |
| AA             | 3867     | 192| –12.32| 6.63| 0.15 | 0.9387|
| Aa             | 1        | 1  | –12.32| 0   | 0.15 | 0.9387|
| aa             | 1        | 1  | –12.32| 0   | 0.15 | 0.9387|
| 4 kHz          |          |    |      |     |      |       |
| AA             | 3880     | 192| –13.94| 7.11| 0.06 | 0.9387|
| Aa             | 1        | 1  | –13.94| 0   | 0.06 | 0.9387|
| aa             | 1        | 1  | –13.94| 0   | 0.06 | 0.9387|
| Total response |          |    |      |     |      |       |
| AA             | 3890     | 193| 9.45 | 5.50| 0.10 | 0.9026|
| Aa             | 1        | 1  | 9.45 | 0   | 0.10 | 0.9026|
| Right ear      |          |    |      |     |      |       |
| TEOAE amplitude (dB SPL) |          |    |      |     |      |       |
| 1 kHz          |          |    |      |     |      |       |
| AA             | 3668     | 190| –7.62| 6.93| 0.04 | 0.9637|
| Aa             | 1        | 1  | –7.62| 0   | 0.04 | 0.9637|
| aa             | 1        | 1  | –7.62| 0   | 0.04 | 0.9637|
| 2 kHz          |          |    |      |     |      |       |
| AA             | 3727     | 192| –9.00| 6.52| 0.00 | 0.9970|
| Aa             | 1        | 1  | –9.00| 0   | 0.00 | 0.9970|
| aa             | 1        | 1  | –9.00| 0   | 0.00 | 0.9970|
| 3 kHz          |          |    |      |     |      |       |
| AA             | 3722     | 193| –11.38| 7.17| 0.23 | 0.1074|
| Aa             | 1        | 1  | –11.38| 0   | 0.23 | 0.1074|
| aa             | 1        | 1  | –11.38| 0   | 0.23 | 0.1074|
| 4 kHz          |          |    |      |     |      |       |
| AA             | 3716     | 193| –13.54| 7.41| 0.36 | 0.6982|
| Aa             | 1        | 1  | –13.54| 0   | 0.36 | 0.6982|
| aa             | 1        | 1  | –13.54| 0   | 0.36 | 0.6982|
| Total response |          |    |      |     |      |       |
| AA             | 3738     | 192| 10.29| 5.39| 0.17 | 0.8470|
| Aa             | 1        | 1  | 10.29| 0   | 0.17 | 0.8470|
| Left ear       |          |    |      |     |      |       |
| Tympanometry   |          |    |      |     |      |       |
| Middle ear compliance (cm³) |        |    |      |     |      |       |
| AA             | 4767     | 225| 0.64 | 0.42| 0.22 | 0.7987|
| Aa             | 2        | 0.55| 0.07 |     |      |       |
| Middle ear pressure (daPa) |       |    |      |     |      |       |
| AA             | 4776     | 226| –39.73| 62.29| 0.32 | 0.7292|
| Aa             | 2        | 2  | –39.73| 0   | 0.32 | 0.7292|
| Right ear      |          |    |      |     |      |       |
| Tympanometry   |          |    |      |     |      |       |
| Middle ear compliance (cm³) |        |    |      |     |      |       |
| AA             | 4768     | 228| 0.62 | 0.42| 1.60 | 0.2028|
| Aa             | 2        | 0.45| 0.07 |     |      |       |
| Middle ear pressure (daPa) |       |    |      |     |      |       |
| AA             | 4780     | 227| –39.37| 61.61| 0.14 | 0.8712|
| Aa             | 2        | 2  | –39.37| 0   | 0.14 | 0.8712|
| doi:10.1371/journal.pone.0005784.t002 | | | | | |
Table 3. Effect of carrier (1) (FLG R501X or FLG 2282del4) versus non-carrier (0) status on 30 hearing variables as tested by one-way ANOVA tests.

| Status | N  | Mean | SD  | F    | P      |
|--------|----|------|-----|------|--------|
|        |    |      |     |      |        |
| **Right ear** | | | | | |
| Air conduction hearing threshold (dB HL) | | | | | |
| 0.5 kHz | 0  | 4716 | 6.18 | 7.21 | 0.62 | 0.4308 |
|           | 1  | 455  | 6.46 | 7.32 |      |        |
| 1 kHz    | 0  | 4790 | 4.33 | 7.57 | 1.42 | 0.2333 |
|           | 1  | 459  | 4.77 | 8.05 |      |        |
| 2 kHz    | 0  | 4789 | 4.02 | 7.26 | 0.14 | 0.7041 |
|           | 1  | 459  | 4.15 | 7.41 |      |        |
| 4 kHz    | 0  | 4788 | 3.83 | 8.31 | 0.00 | 0.9926 |
|           | 1  | 459  | 3.82 | 8.35 |      |        |
| 8 kHz    | 0  | 4700 | 9.03 | 10.09| 0.02 | 0.8892 |
|           | 1  | 450  | 9.10 | 9.63 |      |        |
| Average 0.5, 1, 2, 4, 8 kHz | 0  | 4694 | 5.44 | 6.28 | 0.56 | 0.4543 |
|           | 1  | 449  | 5.67 | 6.56 |      |        |
| Bone conduction hearing threshold (dB HL) | | | | | |
| 0.5 kHz  | 0  | 4628 | −1.25 | 6.47 | 0.05 | 0.8241 |
|           | 1  | 446  | −1.18 | 6.93 |      |        |
| 1 kHz    | 0  | 4765 | −2.31 | 6.42 | 0.31 | 0.5772 |
|           | 1  | 457  | −2.13 | 7.19 |      |        |
| 2 kHz    | 0  | 4637 | 0.94 | 7.18 | 0.01 | 0.9038 |
|           | 1  | 446  | 0.90 | 7.82 |      |        |
| Average 0.5, 1, 2 kHz | 0  | 4623 | −0.90 | 5.28 | 0.14 | 0.7128 |
|           | 1  | 446  | −0.80 | 6.22 |      |        |
| TEOAE amplitude (dB SPL) | | | | | |
| 1 kHz    | 0  | 3677 | −8.75 | 6.98 | 0.02 | 0.8939 |
|           | 1  | 352  | −8.70 | 7.08 |      |        |
| 2 kHz    | 0  | 3709 | −10.14 | 6.73 | 0.45 | 0.5047 |
|           | 1  | 355  | −10.39 | 6.71 |      |        |
| 3 kHz    | 0  | 3704 | −12.11 | 7.17 | 1.30 | 0.2538 |
|           | 1  | 355  | −12.56 | 6.83 |      |        |
| 4 kHz    | 0  | 3717 | −13.80 | 7.59 | 0.58 | 0.4452 |
|           | 1  | 355  | −14.12 | 7.01 |      |        |
| Total response | 0  | 3727 | 9.64 | 5.70 | 0.31 | 0.5792 |
|           | 1  | 356  | 9.46 | 5.45 |      |        |
| **Left ear** | | | | | |
| Air conduction hearing threshold (dB HL) | | | | | |
| 0.5 kHz  | 0  | 4718 | 6.48 | 7.31 | 0.04 | 0.8508 |
|           | 1  | 455  | 6.42 | 6.90 |      |        |
| 1 kHz    | 0  | 4789 | 4.51 | 7.66 | 0.58 | 0.4454 |
|           | 1  | 459  | 4.23 | 7.08 |      |        |
| 2 kHz    | 0  | 4787 | 4.21 | 7.50 | 0.02 | 0.8981 |
|           | 1  | 459  | 4.26 | 7.25 |      |        |
| 4 kHz    | 0  | 4786 | 4.69 | 8.60 | 0.71 | 0.3990 |
|           | 1  | 458  | 4.33 | 7.91 |      |        |
| 8 kHz    | 0  | 4699 | 9.18 | 10.35 | 0.86 | 0.3545 |
|           | 1  | 449  | 8.71 | 10.13 |      |        |
| Average 0.5, 1, 2, 4 kHz | 0  | 4697 | 5.77 | 6.27 | 0.36 | 0.5510 |
|           | 1  | 448  | 5.59 | 6.20 |      |        |
| Bone conduction hearing threshold (dB HL) | | | | | |
| 0.5 kHz  | 0  | 4628 | −1.25 | 6.47 | 0.05 | 0.8241 |
|           | 1  | 446  | −1.18 | 6.93 |      |        |
| 1 kHz    | 0  | 4765 | −2.31 | 6.42 | 0.31 | 0.5772 |
|           | 1  | 457  | −2.13 | 7.19 |      |        |
| 2 kHz    | 0  | 4637 | 0.94 | 7.18 | 0.01 | 0.9038 |
|           | 1  | 446  | 0.90 | 7.82 |      |        |
| Average 0.5, 1 kHz | 0  | 4623 | −0.90 | 5.28 | 0.14 | 0.7128 |
|           | 1  | 446  | −0.80 | 6.22 |      |        |
| TEOAE amplitude (dB SPL) | | | | | |
| 1 kHz    | 0  | 3677 | −8.75 | 6.98 | 0.02 | 0.8939 |
|           | 1  | 352  | −8.70 | 7.08 |      |        |
| 2 kHz    | 0  | 3709 | −10.14 | 6.73 | 0.45 | 0.5047 |
|           | 1  | 355  | −10.39 | 6.71 |      |        |
| 3 kHz    | 0  | 3704 | −12.11 | 7.17 | 1.30 | 0.2538 |
|           | 1  | 355  | −12.56 | 6.83 |      |        |
| 4 kHz    | 0  | 3717 | −13.80 | 7.59 | 0.58 | 0.4452 |
|           | 1  | 355  | −14.12 | 7.01 |      |        |
| Total response | 0  | 3727 | 9.64 | 5.70 | 0.31 | 0.5792 |
|           | 1  | 356  | 9.46 | 5.45 |      |        |
| **Right ear** | | | | | |
| TEOAE amplitude (dB SPL) | | | | | |
| 1 kHz    | 0  | 3515 | −7.66 | 6.91 | 1.46 | 0.2271 |
|           | 1  | 343  | −7.19 | 7.02 |      |        |
| 2 kHz    | 0  | 3574 | −9.04 | 6.54 | 1.54 | 0.2153 |
mutations associated with better hearing thresholds/TEOAE in cases with type A tympanograms (i.e. no middle ear effusion).

Statistical analyses

The associations between each of the two mutations and continuous variables were tested by means of one-way ANOVA analyses. Analyses involving the discrete variable bilateral middle ear effusion were performed by means of a Pearson $\chi^2$ contingency test. All analyses were performed in SPSS ver. 15.0.

Results

Complete data on genotypic data and at least one hearing variable were available for 5,377 children.

There were no significant deviations from Hardy-Weinberg equilibrium for the mutations analysed (data not shown). The allele frequencies observed for R501X (0.021) and 2282del4 (0.023) are consistent with the allele frequencies observed in other studies (ranging from 0.021 to 0.041 for R501X, and from 0.005 to 0.019 for 2282del4) [9].

Tables 1 and 2 show the results from the association tests between each of the 28 variables analysed and R501X and 2282del4 respectively. There was no single nominal association between any of the 28 variables and R501X. For 2282del4, we found a nominal association ($P = 0.0057$) with air conduction hearing threshold level at 2 kHz on the right ear, but no association with the same hearing threshold for the left ear ($P = 0.6855$). The audiograms for two children homozygous for 2282del4 (who averaged right ear 2 kHz data which was significant; $P = 0.0057$) indicated an isolated right ear high threshold (35 dB) for one subject, whereas the other subject and both left ear values were near the population average. No association was found between the 28 variables and overall FLG mutation carrier vs non-carrier status (Table 3). The results observed when considering the combined homozygote status association (compound heterozygous for both mutations plus homozygotes for 2282del4) were not remarkable (data not shown).

There was no association with better versus worse hearing in either of the two mutations (data not shown). The analyses involving enhanced or diminished bone conduction did not show evidence of association with R501X (data not shown). A nominal association ($P = 0.013$) was found between the average bone conduction better versus worse hearing and 2282del4 (data not shown). The analyses involving better versus worse cochlear function/middle ear transmission did not show evidence of association with R501X or 2282del4 (data not shown). The analysis of association between cases with type A tympanograms (i.e. no middle ear effusion) and the hearing variables showed no evidence of association with either mutation.

Discussion

This work is the first analysis of two common filaggrin mutations (R501X and 2282del4) for possible effect on hearing phenotypes. It was undertaken in a large ($N = 5,377$) cohort of UK children. These children were analysed in detail for a large number of hearing variables when they were nine years old. We did not find any support for the hypothesis that FLG mutation carrier status, via known expression in the tympanic membrane, might affect hearing. Two instances of nominal association were found in our study. However, both instances may be the result of type-I error, since we conducted 140 tests. The correction for multiple testing results in a limit of $P = 0.0004$ to reject the null
hypothesis for an \( \alpha = 0.05 \), a limit well below the minimum \( P \) value observed in our study. Furthermore, these nominal associations were not consistent between the two different FLG mutations.

Our study was well powered (\( N = 5,377 \)). This reduces the chance of false negatives. Therefore, our conclusions of no effect of R501X and 2282del4 on hearing thresholds or otoacoustic emissions are robust. The same applies to our results indicating no effect of FLG mutations on tympanic membrane compliance, middle ear pressure or incidence of middle ear effusion. However, our results derive from a UK sample of nine year old children. It remains possible that there might be genotype-dependent effects in other age ranges and populations.

Acknowledgments

We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses.

Author Contributions

Conceived and designed the experiments: SR AJH JH INMD. Performed the experiments: WHIM ADI CNAP JH. Analyzed the data: SR AJH RG. Contributed reagents/materials/analysis tools: WHIM ADI CNAP GDS JH. Wrote the paper: SR INMD.

References

1. McGrath JA, Uitto J (2008) The filaggrin story: novel insights into skin-barrier function and disease. Trends Mol Med 14: 20–27.
2. McGrath JA (2008) Filaggrin and the great epidermal barrier grief. Australas J Dermatol 49: 67–73.
3. Kinley-Grant LJ, Idler WW, Bernstein IA, Parry DA, Cannizzaro L, et al. (1989) Characterization of a cDNA clone encoding human filaggrin and localization of the gene to chromosome region 1q21. Proc Natl Acad Sci U S A 86: 4848–4852.
4. Henderson J, Northstone K, Lee SP, Liao H, Zhao Y, et al. (2008) The burden of disease associated with filaggrin mutations: a population-based, longitudinal birth cohort study. J Allergy Clin Immunol 121: 872–877.
5. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, et al. (2006) Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 38: 441–446.
6. Sandilands A, Terron-Kwiatkowski A, Hull PR, O’Regan GM, Clayton TH, et al. (2007) Comprehensive analysis of the gene encoding filaggrin uncover the presence of prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. Nat Genet 39: 650–654.
7. Smith FJ, Irvine AD, Terron-Kwiatkowski A, Sandilands A, Campbell LE, et al. (2006) Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet 38: 337–342.
8. Hoffjan S, Stemmler S (2007) On the role of the epidermal differentiation complex in ichthyosis vulgaris, atopic dermatitis and psoriasis. Br J Dermatol 157: 441–449.
9. Gruber R, Janecke AR, Fauth C, Uerzenmann G, Fritsch PO, et al. (2007) Filaggrin mutations p.R501X and c.2282del4 in ichthyosis vulgaris. Eur J Hum Genet 15: 179–184.
10. Broekxert D (1995) The tympanic membrane: a biochemical updating of structural components. Acta Otoaryngolog Belg 49: 127–137.
11. Chao WY, Huang CC (1989) Localization of filaggrin in human middle ear cholesteatoma. Acta Otoaryngolog 107: 249–253.
12. Stammberger M, Bujia J, Kastenbauer E (1995) Alteration of epidermal differentiation in middle ear cholesteatoma. Acta Otoaryngolog Belg 49: 127–137.
13. Jones RW, Ring S, Tyfield L, Hanvas R, Simmons H, et al. (2000) A new human genetic resource: a DNA bank established as part of the Avon longitudinal study of pregnancy and childhood (ALSPAC). Eur J Hum Genet 8: 653–660.
14. Golding J, Pembery M, Jones R (2001) ALSPAC: the Avon Longitudinal Study of Parents and Children. I. Study methodology. Paediatr Perinat Epidemiol 15: 74–87.

Table 4. Effect of FLG R501X and 2282del4 on bilateral middle ear effusion.

|           | R501X |   | 2282del4 |   |
|-----------|-------|---|----------|---|
|           | AA    | Aa| AA       | Aa| aa|
| Bilateral | 3881  | 162| 3856     | 186| 2 |
| Expected  | 3874.00| 169.00| 3861.22| 181.25| 1.53|
| Bilateral | 62    | 2 | 63       | 1 | 0 |
| Expected  | 61.32| 2.68| 61.11    | 2.87| 0.02|
| Bilateral | 121   | 3 | 118      | 6 | 0 |
| Expected  | 118.82| 5.18| 118.40   | 5.56| 0.05|
| Bilateral | 58    | 5 | 61       | 2 | 0 |
| Expected  | 60.37| 2.63| 60.15    | 2.82| 0.02|
| Bilateral | 164   | 8 | 168      | 4 | 0 |
| Expected  | 164.81| 7.19| 164.23   | 7.71| 0.07|
| Other     | 780   | 41| 783      | 38| 0 |
| Expected  | 786.68| 34.32| 783.89   | 36.80| 0.31|
| Pearson \( \chi^2 \) | \( P = 0.402 \) | \( P = 0.937 \) |

Type A indicates normal middle ear function. Type B indicates middle ear effusion. Type C1 indicates slight negative middle ear pressure. Type C2 indicates negative middle ear pressure. Other indicates grommet, perforation, or type C2 tympanogram in at least one ear. Expected correspond to the expected contingency values were the null hypothesis is that the probabilities for each phenotype are independent of the mutation.

doi:10.1371/journal.pone.0005784.t004